Meeting
2018 ASCO Annual Meeting
A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.
Authors
Olatunji B. Alese
Winship Cancer Institute, Atlanta, GA
Olatunji B. Alese , Walid Labib Shaib , Mehmet Akce , Christina Wu , Bassel F. El-Rayes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT03368963
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS4155)
DOI
10.1200/JCO.2018.36.15_suppl.TPS4155
Abstract #
TPS4155
Poster Bd #
332a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
OniLon: Phase II trial of trifluridine/tipiracil (TAS-102) and nanoliposomal irinotecan (nal-IRI) in advanced colorectal cancer.
First Author: Olatunji B. Alese
Poster
2022 ASCO Annual Meeting
Study protocol of an open-label, single-arm, phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC).
First Author: Linde Kehmann
Poster
2020 ASCO Virtual Scientific Program
A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX).
First Author: Andrew Eugene Hendifar
Poster
2019 Gastrointestinal Cancers Symposium
Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study.
First Author: Yoshito Komatsu